[Illumina Q3 2026 Earnings Call] Illumina Raises Full-Year Guidance to $4.64–$4.66 Billion as NovaSeq X Placements Top 80 and EPS Hits $1.44
Illumina reported Q3 2026 revenue of $1.17B, up 4.7% YoY, and EPS of $1.44. The company raised full-year guidance to $4.64–$4.66B, citing strong clinical demand and NovaSeq X placements. Operating margin was 25%, 100 bps ahead of guidance. Illumina expects 4.5% organic growth in Q4 and high-single-digit growth for 2027.
How this was made
The 30-second read
Why it matters
Guidance raise suggests sustained demand; investors may adjust positions accordingly.
Market read
Earnings beat and guidance lift are likely to move Illumina stock and influence the broader genomics sector.
What to watch
Potential regulatory headwinds in China and supply‑chain constraints could temper growth.
Background
Illumina reported Q3 2026 results with revenue up 4.7% YoY and highlighted NovaSeq X placements.
Ticker impact
Illumina raised FY2026 revenue guidance to $4.64‑$4.66B and EPS to $5.40‑$5.45 after a Q3 beat.
upward pressure as investors price in higher revenue and earnings outlook
Guidance raise of $30M at the midpoint and EPS beat indicate better-than-expected performance, prompting buying interest.
Market effects
Positive outlook for genomics sequencing sector, may lift peers with similar exposure.
Strengthens US biotech sentiment; modest impact on Asian markets.
Reinforces demand for clinical sequencing worldwide, especially in China.
Counterpoint
If guidance is overly optimistic, future quarters could miss expectations, leading to a pull‑back.
Key entities
- ExecutiveJacob Thaysen
CEO of Illumina, provided commentary on demand and guidance.
- ExecutiveAnkur Dhingra
CFO of Illumina, discussed financials and future outlook.



